Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT00091767 |
| Other study ID # |
1270 |
| Secondary ID |
R01HL076285-03 |
| Status |
Completed |
| Phase |
N/A
|
| First received |
September 16, 2004 |
| Last updated |
July 11, 2016 |
| Start date |
September 2004 |
| Est. completion date |
June 2008 |
Study information
| Verified date |
July 2008 |
| Source |
National Heart, Lung, and Blood Institute (NHLBI) |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
United States: Federal Government |
| Study type |
Observational
|
Clinical Trial Summary
To investigate genetic factors that affect asthma severity.
Description:
BACKGROUND:
The TENOR (The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens)
study is an ongoing three-year multi-center observational cohort study of 4756 severe or
difficult-to-treat patients with asthma aged 6 or older. Of this group of asthmatics, 44.6%
meet the National Heart, Lung, and Blood Institute National Asthma Education and Prevention
Program guidelines for severe persistent asthma, 27.5% for moderate persistent asthma, and
27.8% for mild persistent asthma. All subjects were evaluated initially with comprehensive
questionnaires and laboratory testing, and are then seen every 6 months during the remaining
3 years of the study. Phenotypic information collected includes information on asthma
exacerbations, medication use, urgent care visits, quality of life, pulmonary function tests
(spirometry with reversibility), total serum IgE levels, and history of allergies. If
accessed now, before the termination of the TENOR study, this population represents one of
the largest populations of phenotypically characterized difficult-to-treat and severe
asthmatics potentially available for genomic and pharmacogenetic studies. TENOR will finish
at the end of 2004, thus there is a very short time window in which to obtain DNA samples
for genetic studies before the termination of the study. Isolation and storage of DNA from
this well characterized, longitudinal population will serve as a resource not only for the
studies in this grant but also for future genomics and pharmacogenetic studies in asthma.
DESIGN NARRATIVE:
The study investigates genetic factors that affect asthma severity in the TENOR subjects.
The study tests the hypothesis that factors which produce difficult-to-treat and severe
asthma are produced by altered inflammatory responses that are related, at least in part, to
sequence variants (polymorphisms) in genes that regulate inflammation, allergic
responsiveness, and/or affect structural components in the airways. The study also tests the
hypothesis that some patients develop more severe asthma because of genetic differences that
modulate their responses to pharmacologic agents. To test these hypotheses, the following
specific aims will be carried out: 1) Obtain DNA samples from at least 4,000 asthmatics
currently enrolled in the ongoing TENOR study; 2) Determine whether sequence variants
(polymorphisms) in genes that regulate inflammation, cellular responses, and/or tissue
injury and repair are more frequently associated with asthma severity using the baseline
data; 3) Determine the importance of genetic polymorphisms in genes that may be important in
IgE regulation in this population of difficult-to-treat patients with asthma; 4) Evaluate
pharmacogenetic relationships between polymorphisms in the a2 adrenergic receptor (a2AR) in
those subjects on long-acting beta-2-agonists to determine the effect on asthma severity; 5)
Evaluate pharmacologic mechanisms by investigating whether polymorphisms in genes that
regulate responses to asthma therapy are more frequent in severe disease.
